New and emerging immunotherapies and combination approaches are revolutionizing treatment for metastatic urothelial carcinoma (mUC) patients. Tune in to hear experts review insights and lessons learned from an American Oncology Network quality-improvement initiative. Discussions include key challenges in mUC care and actionable steps to improve patient-centered care for patients with mUC.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/latest-evidence-immunotherapy-metastatic-bladder-cancer
- Start Date: 2024-05-03 05:00:00
- End Date: 2024-05-03 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Merck (Any division) - Amount: 50000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology
Subscribe
Login
0 Comments
Oldest